Board Decisions
The Board of Directors at its meeting held on May 29, 2026 (10:00 AM to 2:18 PM IST) took the following decisions:
- Approved Audited Financial Results along with Auditors' Report for Quarter & Financial Year ended March 31, 2026, with unmodified opinion
- Recommended final dividend @ 35% (₹3.50 per share) on Equity Share Capital for FY 2025-26, subject to shareholder approval at ensuing AGM
- Re-appointed M/s K R & Associates, Chartered Accountants (FRN 131846), Vadodara as Internal Auditor for FY 2026-27
- Re-appointed M/s V. M. Patel & Associates, Cost Accountants, Surat as Cost Auditor for FY 2026-27
- Scheduled 45th Annual General Meeting on Monday, September 28, 2026 through Video Conferencing/Other Audio Visual Means
- Fixed Register of Members and Share Transfer Books closure from Tuesday, September 22, 2026 to Monday, September 28, 2026 (both days inclusive) for AGM
- Set Record Date as Monday, September 21, 2026 for final dividend payment if approved by shareholders
- Final dividend, if declared at AGM, shall be paid on or before October 26, 2026
Financial Results Highlights (₹ in lakhs)
Quarter Ended March 31, 2026 (Audited):
- Total Income: ₹2,111.33
- Total Expenses: ₹1,937.65
- Profit Before Tax: ₹173.68
- Net Profit After Tax: ₹130.01
- Earnings Per Share (Basic & Diluted): ₹10.83
Quarter Ended December 31, 2025 (Unaudited):
- Total Income: ₹1,866.27
- Total Expenses: ₹1,683.80
- Profit Before Tax: ₹142.98
- Net Profit After Tax: ₹99.75
Quarter Ended March 31, 2025 (Audited):
- Total Income: ₹2,084.36
- Total Expenses: ₹1,939.67
- Profit Before Tax: ₹144.69
- Net Profit After Tax: ₹99.32
Year Ended March 31, 2026 (Audited):
- Total Income: ₹7,789.18
- Total Expenses: ₹7,085.97
- Profit Before Exceptional Items and Tax: ₹703.21
- Exceptional Items: ₹39.49
- Profit Before Tax: ₹663.72
- Net Profit After Tax: ₹492.83
- Total Comprehensive Income: ₹492.73
- Earnings Per Share (Basic & Diluted): ₹410.69
Year Ended March 31, 2025 (Audited):
- Total Income: ₹7,616.99
- Total Expenses: ₹7,150.82
- Profit Before Tax: ₹466.17
- Net Profit After Tax: ₹325.49
- Total Comprehensive Income: ₹315.07
- Earnings Per Share (Basic & Diluted): ₹271.21
Exceptional Items
The Company disclosed an exceptional item of ₹39.49 lakhs for the year ended March 31, 2026, representing additional provision towards gratuity liability and leave liability due to implementation of four new Labour Codes effective from November 21, 2025. The Central Government notified final Central Rules on May 8, 2026, while state rules are still being finalized.
Balance Sheet Position as at March 31, 2026 (₹ in lakhs)
- Total Assets: ₹7,908.22
- Equity Share Capital: ₹120.00
- Other Equity: ₹5,687.63
- Non-current Liabilities: ₹932.04 (including Long Term Borrowings ₹674.01, Lease Liabilities ₹29.24, Other Financial Liabilities ₹43.63, Provisions ₹156.85, Deferred Tax Liability ₹28.31)
- Current Liabilities: ₹1,168.18
Cash Flow Statement for Year Ended March 31, 2026 (₹ in lakhs)
- Cash Generated from Operations: ₹549.51
- Net Cash Flow from Operating Activities: ₹423.96
- Net Cash used in Investing Activities: ₹316.51
- Net Cash used in Financing Activities: ₹263.18
- Net Increase in Cash and Cash Equivalents: ₹370.63
- Cash and Cash Equivalents at year-end: ₹589.95 (including earmarked balances ₹57.70)
Auditors and Compliance
- Statutory Auditors: M/s Naresh & Co., Chartered Accountants (FRN 106928W) issued unmodified opinion on financial results
- Internal Auditor: M/s K R & Associates (FRN 131846) reappointed for FY 2026-27
- Cost Auditor: M/s V. M. Patel & Associates reappointed for FY 2026-27
- Financial results prepared in accordance with Indian Accounting Standards and SEBI LODR Regulations
- Company operates in single segment: "Pharmaceuticals Products"
Dividend Timeline
- Record Date: September 21, 2026
- AGM Date: September 28, 2026
- Dividend Payment Date: On or before October 26, 2026 (if approved)